Diabetologia:利拉鲁肽或可逆转胰岛素相关体重增加(ELEGANT研究)

2014-07-23 desperado-c 丁香园

对起始胰岛素治疗后体重显著增加的2型糖尿病患者而言,其最佳降血糖治疗方案仍不清楚。为此,来自荷兰内梅亨大学医学中心的Helena M. de Wit教授及其团队进行了一项研究,在胰岛素治疗后体重显著增加的2型糖尿病患者中,探讨加用胰高血糖素样肽–1(GLP–1)在维持血糖控制的同时,是否能逆转胰岛素相关体重增加,并与标准胰岛素治疗方案进行比较。该研究结果在线发表在2014月06月20日的Diabe

对起始胰岛素治疗后体重显著增加的2型糖尿病患者而言,其最佳降血糖治疗方案仍不清楚。
为此,来自荷兰内梅亨大学医学中心的Helena M. de Wit教授及其团队进行了一项研究,在胰岛素治疗后体重显著增加的2型糖尿病患者中,探讨加用胰高血糖素样肽–1(GLP–1)在维持血糖控制的同时,是否能逆转胰岛素相关体重增加,并与标准胰岛素治疗方案进行比较。该研究结果在线发表在2014月06月20日的Diabetologia杂志上。

该研究是一项为期26周的随机对照试验(ELEGANT),在荷兰一家教学医院和一家非教学医院的门诊部进行,共招募了50例短期胰岛素治疗(≤16月)期间体重增加≥4kg的成年2型糖尿病患者。使用计算机产生随机序列号,将受试者随机分到每天加用1.8mg利拉鲁肽组(26例)或继续标准治疗组(24例)。每4–6周对受试者进行一项体重、血糖控制情况和不良事件的评估。主要终点为治疗26周后两组间体重的差异。

该研究50例患者的平均年龄为58岁,平均BMI为33kg/m2,平均HbA1c为7.4% [57 mmol/mol],最终共有47例(94%) 患者完成这项研究。结果发现,26周治疗后,利拉鲁肽组体重下降了4.5kg,标准治疗组体重增加了0.9kg(平均差异-5.2 kg [95% CI -6.7, -3.6 kg]; p < 0.001)。此外,利拉鲁肽组HbA1c水平下降了0.77%,标准治疗组HbA1c水平增加了0.01%(差值为-0.74%) ([95% CI -1.08%, -0.41%] ; p < 0.001),利拉鲁肽组每天胰岛素剂量减少了29U/天,而标准治疗组每天胰岛素剂量增加了5U/天。利拉鲁肽组中有5例(19%)患者可完全停用胰岛素。而且,利拉鲁肽治疗耐受性良好,研究期间未发生严重不良事件或严重低血糖。

该研究提示,对胰岛素治疗后体重显著增加的患者而言,在治疗方案中加用利拉鲁肽可有效降低体重、减少胰岛素用量、改善血糖控制,因此,与继续标准胰岛素治疗相比,加用利拉鲁肽是一个有价值的治疗选择。

不过,MedSci小编也提醒,这仅是一项小规模的随机对照研究,最终还需要大规模临床研究进一步证实。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1785167, encodeId=f5791e851678b, content=<a href='/topic/show?id=7c23666e3b' target=_blank style='color:#2F92EE;'>#ELEGANT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6667, encryptionId=7c23666e3b, topicName=ELEGANT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Tue Mar 10 04:35:00 CST 2015, time=2015-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20686, encodeId=025b206860e, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:30:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636915, encodeId=6f9b1636915ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 20 01:35:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759476, encodeId=3b461e5947614, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 21 18:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749492, encodeId=5f881e49492b7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 25 06:35:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298189, encodeId=e87d1298189b2, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jul 25 06:35:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1785167, encodeId=f5791e851678b, content=<a href='/topic/show?id=7c23666e3b' target=_blank style='color:#2F92EE;'>#ELEGANT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6667, encryptionId=7c23666e3b, topicName=ELEGANT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Tue Mar 10 04:35:00 CST 2015, time=2015-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20686, encodeId=025b206860e, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:30:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636915, encodeId=6f9b1636915ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 20 01:35:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759476, encodeId=3b461e5947614, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 21 18:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749492, encodeId=5f881e49492b7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 25 06:35:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298189, encodeId=e87d1298189b2, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jul 25 06:35:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
    2015-04-11 x35042875

    糖尿病肾病进展风险的关系没有发现。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1785167, encodeId=f5791e851678b, content=<a href='/topic/show?id=7c23666e3b' target=_blank style='color:#2F92EE;'>#ELEGANT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6667, encryptionId=7c23666e3b, topicName=ELEGANT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Tue Mar 10 04:35:00 CST 2015, time=2015-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20686, encodeId=025b206860e, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:30:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636915, encodeId=6f9b1636915ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 20 01:35:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759476, encodeId=3b461e5947614, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 21 18:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749492, encodeId=5f881e49492b7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 25 06:35:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298189, encodeId=e87d1298189b2, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jul 25 06:35:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1785167, encodeId=f5791e851678b, content=<a href='/topic/show?id=7c23666e3b' target=_blank style='color:#2F92EE;'>#ELEGANT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6667, encryptionId=7c23666e3b, topicName=ELEGANT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Tue Mar 10 04:35:00 CST 2015, time=2015-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20686, encodeId=025b206860e, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:30:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636915, encodeId=6f9b1636915ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 20 01:35:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759476, encodeId=3b461e5947614, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 21 18:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749492, encodeId=5f881e49492b7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 25 06:35:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298189, encodeId=e87d1298189b2, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jul 25 06:35:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
    2014-08-21 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=1785167, encodeId=f5791e851678b, content=<a href='/topic/show?id=7c23666e3b' target=_blank style='color:#2F92EE;'>#ELEGANT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6667, encryptionId=7c23666e3b, topicName=ELEGANT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Tue Mar 10 04:35:00 CST 2015, time=2015-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20686, encodeId=025b206860e, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:30:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636915, encodeId=6f9b1636915ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 20 01:35:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759476, encodeId=3b461e5947614, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 21 18:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749492, encodeId=5f881e49492b7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 25 06:35:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298189, encodeId=e87d1298189b2, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jul 25 06:35:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
    2015-06-25 baoya
  6. [GetPortalCommentsPageByObjectIdResponse(id=1785167, encodeId=f5791e851678b, content=<a href='/topic/show?id=7c23666e3b' target=_blank style='color:#2F92EE;'>#ELEGANT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6667, encryptionId=7c23666e3b, topicName=ELEGANT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Tue Mar 10 04:35:00 CST 2015, time=2015-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20686, encodeId=025b206860e, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:30:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636915, encodeId=6f9b1636915ea, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jun 20 01:35:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759476, encodeId=3b461e5947614, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 21 18:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749492, encodeId=5f881e49492b7, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Jun 25 06:35:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298189, encodeId=e87d1298189b2, content=<a href='/topic/show?id=3379266918f' target=_blank style='color:#2F92EE;'>#体重增加#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26691, encryptionId=3379266918f, topicName=体重增加)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jul 25 06:35:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]

相关资讯

利拉鲁肽胰腺炎和癌症危险

 6月13日,由于一项近期对医疗保健从业者的评估发现,一些初级保健从业者并未完全知晓胰高糖素样肽-1类似物利拉鲁肽相关的严重危险,因此诺和诺德公司通过美国FDA发布了重要的利拉鲁肽安全信息,提醒医生利拉鲁肽相关的胰腺炎和甲状腺C细胞肿瘤危险。   研究表明,在临床相关暴露剂量下,利拉鲁肽在大鼠和小鼠中,可引发剂量依赖性和治疗时间依赖性甲状腺C细胞肿瘤。目前,并不清楚利拉鲁肽是否在人体内也引发甲

Lancet:利拉鲁肽每和艾塞那肽均可改善2型糖尿病患者血糖控制

  现已证实,胰高糖素样肽(GLP)-1激动剂艾塞那肽和利拉鲁肽可改善2型糖尿病患者血糖控制并减轻体重。DURATION-6(比较艾塞那肽每周1次与利拉鲁肽每日1次治疗2型糖尿病)最新结果表明,利拉鲁肽每日一次和艾塞那肽每周一次均可改善血糖控制,利拉鲁肽组血糖降低更多。结合此结果和药物的注射频率和耐受性,可有助于2型糖尿病患者的治疗决策。该研究11月7日在线发表于《柳叶刀》(Lancet)杂志。

礼来制药降糖新药Dulaglutide非劣效于利拉鲁肽(Liraglutide) (AWARD-6研究)

2型糖尿病头对头III期临床试验证实:礼来制药研发的每周一次的Dulaglutide非劣效于Liraglutide在第六项AWARD系列研究中每周一次的Dulaglutide达到主要终点。     礼来制药(NYSE: LLY)于今日公布了第六项AWARD(评估LY2189265每周一次给药在糖尿病中的疗效)研究的主要阳性结果。此项研究主要针对用于2型糖尿

Lancet Diab & Endo:利拉鲁肽和阿必鲁肽治疗糖尿病,孰优?

美国学者在口服降糖药控制血糖不佳的2型糖尿病患者中对比了两种胰高血糖素样肽-1受体激动剂[每周一次的阿必鲁肽(albiglutide)和每日一次的利拉鲁肽]的疗效,结果表明,每日一次的利拉鲁肽降糖化血红蛋白(HbA1c)幅度更大,而接受阿必鲁肽的受试者出现了较多的注射部位反应和较少的胃肠道不良事件。文章2月6日在线发表于《柳叶刀·糖尿病与内分泌学》(The Lancet Diabetes

利拉鲁肽在亚洲T2DM的研究分析

  人胰高血糖素样肽1(GLP-1)类似物利拉鲁肽是全球首个人GLP-1类似物,既往主要在西方人群中进行的Ⅲ期临床研究结果已显示,其具有有效全面降低血糖、低血糖风险低、改善β细胞功能、减轻体重、降低血压等效应。然而,对于东方2型糖尿病人群,利拉鲁肽的疗效如何呢?就此问题,笔者等在亚洲2 型糖尿病患者中完成的研究证实,利拉鲁肽在东方人群中同样具有上述疗效,其研究结果已于2011年1月正式发表 [Di

Diabetes Care:二甲双胍联合利拉鲁肽+胰岛素序贯方案治疗2型糖尿病

  一项多国研究报告,在二甲双胍治疗血糖控制不佳的2型糖尿病患者中,序贯加用利拉鲁肽和地特胰岛素的强化治疗方案可被多数患者耐受,患者血糖控制佳、体重持续减轻且低血糖发生率低。研究5月14日在线发表于《糖尿病护理》(Diabetes Care)。   该研究纳入988例二甲双胍治疗血糖控制不佳的2型糖尿病患者,加用利拉鲁肽1.8mg/d治疗12周(导入期)后糖化血红蛋白(HbA1c)仍≥7%的患者